Roche remained the No.1 pharma company in 2020, with a
slight dip in prescription drug revenue by 1.6%. It was also the top
R&D spender with $11.3 billion, an increase of 9.8% from the
previous year.
Novartis was at the No. 2 spot with a 2.4% jump in sales in 2020. AbbVie jumped to the 3rd spot with the acquisition of Allergan. Humira is AbbVie's highest-grossing product in immunology, as it alone brought in a revenue of $19.8 billion in 2020.
The companies developing vaccines for COVID-19 also saw an increase in their brand value. Pfizer's brand grew by 6%, followed by 18% for AstraZeneca and 58% for China’s Sinopharm.
(Rx=prescription sales)
Novartis was at the No. 2 spot with a 2.4% jump in sales in 2020. AbbVie jumped to the 3rd spot with the acquisition of Allergan. Humira is AbbVie's highest-grossing product in immunology, as it alone brought in a revenue of $19.8 billion in 2020.
The companies developing vaccines for COVID-19 also saw an increase in their brand value. Pfizer's brand grew by 6%, followed by 18% for AstraZeneca and 58% for China’s Sinopharm.
(Rx=prescription sales)
Comments
Post a Comment